Orforglipron's Mechanism of Action
As a GLP-1 receptor agonist, orforglipron works by binding to the GLP-1 receptor on the surface of pancreatic beta cells.
This binding activates downstream signaling pathways that promote weight loss and glycemic control by increasing insulin sensitivity and decreasing glucagon levels.
Achieving Significant Weight Loss
The Phase 3 ACHIEVE trial demonstrated significant reductions in body mass index (BMI) with orforglipron compared to placebo.
- Mean change from baseline in BMI: 4.5 kg/m2 with orforglipron vs. -0.6 kg/m2 with placebo (ClinicalTrials.gov)
- A 26% reduction in BMI was observed with orforglipron compared to placebo.
Glycemic Control and HbA1c Reductions
Orforglipron also showed significant reductions in glycated hemoglobin (HbA1c) levels compared to placebo.
- A 1.4% reduction in HbA1c with orforglipron vs. a -0.6% reduction with placebo (ClinicalTrials.gov)
- A significant improvement in glycemic control was observed with orforglipron compared to placebo.
Conclusion
The Orforglipron Phase 3 ACHIEVE trial provides promising results for oral GLP-1 weight loss and glycemic endpoints. For clinicians, this means a potential new treatment option with fewer injections required while maintaining efficacy.